Introduction: The Growing Burden of Stroke and Diabetes

The management of acute ischemic stroke has evolved remarkably over the past two decades. Endovascular revascularization now stands as the standard of care for emergent large vessel occlusion in eligible patients. However, metabolic comorbidities frequently complicate clinical presentations, triage, and subsequent neurological recovery. In particular, interventional teams encounter complex challenges when performing mechanical thrombectomy in diabetes. Diabetes mellitus accelerates systemic atherosclerosis, impairs collateral cerebral perfusion, and intensifies ischemic tissue vulnerability. Despite high rates of successful angiographic recanalization, diabetic individuals historically experience poorer functional independence than non-diabetic peers. Within this expanding metabolic cohort, clinicians distinguish patients based on outpatient pharmacotherapeutic regimens. Chronic insulin dependence denotes prolonged disease duration, profound beta-cell failure, and extensive microvascular damage. Conversely, patients who manage glycemia with oral agents exhibit milder metabolic disruption and superior vascular compliance. Understanding how pre-existing insulin therapy impacts endovascular results remains essential for accurate prognostic counseling and acute care planning. A landmark nationwide study has now delivered comprehensive real-world evidence regarding these distinct subsets. Consequently, these findings offer vital insights into risk stratification for modern stroke centers.

Evaluating National Inpatient Trends Across Two Decades

To assess long-term epidemiological shifts, investigators analyzed real-world data from the National Inpatient Sample between 2006 and 2022. During this seventeen-year period, endovascular intervention transformed from an emerging technique into standard front-line therapy. The researchers evaluated adult hospitalizations for acute ischemic stroke treated with mechanical thrombectomy and concomitant diabetes mellitus. Notably, the study revealed dramatic demographic changes across the healthcare system over time. The proportion of thrombectomy recipients presenting with concomitant diabetes increased from 19.9% in 2006 to 31.5% in 2022. Furthermore, among the diabetic subpopulation, documented long-term insulin dependence nearly doubled, rising from 11.6% to 20.4%. These striking figures illustrate the accelerating dual burden of metabolic syndrome and neurovascular disease in emergency departments. In addition, the investigators assembled a matched cohort using propensity scores combined with machine learning algorithms. This rigorous design balanced baseline characteristics across 7,859 patients, yielding 3,931 insulin-treated individuals and 3,928 non-insulin-treated counterparts. As a result, the authors eliminated confounding factors such as presenting stroke severity, age, and baseline vascular comorbidities. This extensive methodology provided an unprecedented foundation to evaluate post-thrombectomy outcomes.

Primary Endpoints: Discharge Disposition Versus In-Hospital Mortality

The investigators systematically evaluated two primary clinical endpoints: non-home discharge disposition and all-cause in-hospital mortality. After robust machine-learning adjustment, documented insulin use was associated with an adjusted risk difference of +6.8 percentage points for non-home discharge. Therefore, insulin-dependent patients demonstrated a higher likelihood of requiring transfer to skilled nursing facilities or specialized rehabilitation centers. In contrast, in-hospital mortality rates did not differ between the cohorts, registering 13.6% for insulin users versus 14.5% for non-insulin users. Consequently, these reassuring findings suggest that chronic insulin therapy does not directly increase acute procedural fatality following endovascular recanalization. Instead, long-term insulin dependence primarily hampers post-stroke functional recovery and delays independent physical ambulation. Furthermore, pre-existing microvascular disease and chronic end-organ damage reduce functional reserve during acute inpatient rehabilitation. Clinicians must recognize that achieving successful arterial recanalization does not immediately guarantee an uneventful return home. Because diabetes chronicity drives subtle neurologic disability, multi-disciplinary care teams should initiate proactive discharge planning early for insulin-requiring patients. In this manner, healthcare systems can allocate appropriate physical and occupational therapy resources promptly.

Complication Paradox: Peri-Procedural Safety in Thrombectomy

Intriguingly, the secondary analyses revealed an unexpected pattern regarding peri-procedural adverse events and acute hospital complications. Patients with documented insulin therapy experienced lower rates of post-procedural intracranial hemorrhage, demonstrating an adjusted risk difference of -4.8 percentage points. Similarly, insulin-coded status was associated with fewer pulmonary complications, reflecting a meaningful risk reduction of -3.6 percentage points. Moreover, documented neurological complications decreased by -0.8 percentage points among chronic insulin users. Although these associations demonstrated borderline statistical significance without multiplicity correction, they challenge conventional clinical expectations. Typically, physicians anticipate higher hemorrhagic conversion risks in advanced diabetes due to microvascular endothelial fragility and blood-brain barrier disruption. However, these counterintuitive results may reflect differential practice patterns in neuro-intensive care units. Specifically, stroke teams often manage insulin-dependent patients under heightened surveillance protocols with rigorous hemodynamic and glycemic monitoring. Furthermore, clinicians might avoid aggressive antithrombotics in high-risk diabetic patients, inadvertently shielding them from secondary hemorrhagic conversion. Nevertheless, researchers emphasize that administrative databases lack granular intra-arterial hemodynamic information. Therefore, neurointerventionalists must interpret these apparent protective associations cautiously rather than viewing insulin as an active neuroprotective agent.

Mechanisms and Clinical Stewardship of Mechanical Thrombectomy in Diabetes

Several distinct pathophysiological mechanisms explain why mechanical thrombectomy in diabetes yields discordant functional outcomes despite successful angiographic recanalization. First, chronic hyperglycemia drives non-enzymatic tissue glycation, producing advanced glycation end-products that stiffen cerebral microvessels and degrade vascular integrity. Consequently, these microvascular alterations compromise leptomeningeal collateral circulation, which normally sustains penumbral brain tissue before mechanical recanalization. In addition, chronic insulin resistance promotes systemic neuroinflammation and exacerbates reperfusion injury upon arterial reopening. When endovascular catheters restore macrovascular blood flow, the microvascular bed often fails to reperfuse adequately. Pathologists describe this phenomenon as the "no-reflow" state, which stems from microcirculatory thrombosis and severe pericyte edema. Furthermore, autonomic neuropathy impairs cardiovascular reflexes, predisposing patients to post-stroke orthostatic hypotension and prolonged immobility. As a result, affected individuals face greater physical barriers during inpatient rehabilitation. Clinicians should never withhold endovascular thrombectomy from insulin-dependent individuals, because acute revascularization prevents catastrophic neurological mortality. However, medical teams must maintain pragmatic glycemic stewardship, avoiding severe hyperglycemia and iatrogenic hypoglycemia during the peri-procedural window. Ultimately, pairing timely mechanical recanalization with proactive metabolic management ensures the best potential recovery for diabetic patients.

Frequently Asked Questions

How does chronic insulin use affect recovery after mechanical thrombectomy?

Chronic insulin use independently predicts higher rates of non-home discharge after thrombectomy. Although procedural recanalization succeeds and in-hospital mortality remains comparable to non-insulin cohorts, long-term insulin dependence reflects chronic microvascular damage, poor collateral supply, and advanced metabolic chronicity. Consequently, these underlying deficits reduce functional recovery and necessitate institutional rehabilitation.

Does insulin therapy increase in-hospital mortality following mechanical thrombectomy?

No, documented insulin therapy does not increase acute in-hospital mortality. Large nationwide registry data demonstrate similar mortality rates between insulin-treated and non-insulin-treated diabetic patients undergoing thrombectomy. Clinicians should therefore offer emergent endovascular intervention to all eligible candidates regardless of their pre-admission insulin status or perceived baseline metabolic severity.

Why did insulin-treated patients experience fewer peri-procedural complications?

The observed reduction in peri-procedural complications among insulin users likely reflects closer neuro-intensive monitoring and cautious hemodynamic management rather than true biological neuroprotection. Intensivists often manage insulin-requiring patients under vigilant protocols with strict blood pressure targets, potentially decreasing secondary hemorrhagic conversion and respiratory complications during the acute hospitalization.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice or replace the judgment of healthcare professionals. Clinical decisions must always account for individual patient circumstances. Refer to the latest local and national guidelines for clinical practice.

References

ElNemer W et al. National trends and comparative outcomes of insulin versus non-insulin therapy in acute ischemic stroke patients treated with mechanical thrombectomy: a retrospective cohort study using the national inpatient sample. Neurosurg Rev. 2026 May 20. doi: 10.1007/s10143-026-04317-7. PMID: 42156589.

Johnston KC et al. Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial. JAMA. 2019;322(4):326-335.

Goyal M et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723-1731.

Powers WJ et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke. 2019;50(12):e344-e418.